Anti-body Coupled T Receptor Therapy Market Size, Industry Share, Latest Trend by Top 10 Leading Players by Forecast 2023 | Exclusive Reportage by Coherent Market Insights

Anti-body coupled T receptor (ACTR) therapy is a type of immunotherapy, used for cancer treatment, in which body’s own immune response is used to kill the cancerous cells. Anti-body coupled T receptor therapy uses T cells from body, engineered it to express specific T cell receptor, multiplying it in lab and then administering it along with targeting antibodies. The major advantage of this therapy is that T cells do not attack normal antigens from blood circulation. However, they do attack antigens attached to cancerous cells. As tumor specific monoclonal antibodies are given together with ACTR T cells, this approach is very much possible. Moreover, it is a cost-efficient therapy, when compared to other cancer therapies. It is possible to have minimum side effects and greater therapeutic benefits, by adjusting the amount of targeting antibody.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/1600

Global Anti-body Coupled T Receptor Therapy Market- Drivers

Increasing occurrence cancer around the globe is expected to drive growth of the global anti-body coupled T receptor therapy market. According to World Health Organization (WHO), cancer is one of the leading non-communicable disease and second leading cause of death globally. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, 8.8 million deaths, and 32.6 million people living with cancer worldwide. Moreover, according Leukemia and Lymphoma Society report, 2017, the U.S. alone is expected to witness prevalence of 816,834 and 80,500 annual new cases of lymphoma. Thus, such high number of cancer patient would propel the global anti-body coupled T receptor therapy market.

Furthermore, ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has side effects such as cytokine release syndrome and neurological toxicity. This is expected to drive adoption of ACTR therapy and thereby propelling growth of the global anti-body coupled T receptor therapy market in the near future. Moreover, CAR-T therapy finds applications in typical cancers such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma. ACTR therapy is also used in solid tumorous cancer such as neuroblastoma and breast cancer.

LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1600

Global Anti-body Coupled T Receptor Therapy Market- Restraints

High cost of product can be a major factor challenging growth of the market. For instance, Kymriah, which is a CAR-T therapy costs around US$ 475,000 per patient. Considering such high cost for CAR-T therapy it can be assumed that anti-body coupled T receptor therapy can also costs on similar line as it works in same segment of immuno oncology, which restrain growth of the global anti-body coupled T receptor therapy market.

Competitive Landscape

Key companies in the market are focused on various strategies such as collaboration and agreement, in order to gain competitive edge in the market. Unum Therapeutics is currently the only company that is working actively in anti-body coupled T receptor therapy. It has several product in its pipeline, and they vary based on the technology used for expression of receptor in patients T cell such as mRNA or viral vector. There is also combination of different monoclonal antibodies to be used for coupling such as rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy found to produce desired therapeutic effects. In 2015, Seattle Genetics, Inc. and Unum Therapeutics, Inc. entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This collaboration would enable study of different combination of the tumor-specific monoclonal antibodies with T receptor and cater to patient specific treatment needs.

Other Related Reports:

CHRONIC LIVER DISEASES THERAPEUTICS MARKET ANALYSIS

PLASMA THERAPY MARKET ANALYSIS

NEUROMYELITIS OPTICS THERAPY MARKET ANALYSIS

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.